The team at Immune-Onc Therapeutics has significant industry experience in bringing innovative biologic treatments to patients with serious diseases. In recent years, T-cell checkpoint inhibitors such as anti-PD-(L)1 have emerged as the standard-of-care for the treatment of multiple solid tumor cancers. Combining our deep expertise in drug development with strategic research collaborations with leading academic institutions and nonprofit patient organizations, we aim to discover and develop new immunomodulatory agents for treatment of autoimmune diseases and cancers. Our efforts are backed by seasoned investors committed to making our vision a reality for patients.
Verified
Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming Scientific and Investor Conferences — Immune-Onc Therapeutics
PALO ALTO, CA, March 3, 2023 / Business Wire / -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today its plans to present on the company’s myeloid biology research and cl
Verified
East/West CEO: Developments in The Oncology Landscape — Immune-Onc Therapeutics
Dr. Charlene Liao, CEO of Immune-Onc Therapeutics, will speak at the East/West CEO conference.
Verified
Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development — Immune-Onc Therapeutics
Gui X. et al. Cancer Immunol. Res. 2019; 7: 1244-1257.
View all products
Keywords
Industries
Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors — Immune-Onc Therapeutics
– Multicenter Phase 1 study to evaluate IO-108 as monotherapy and in combination with anti-PD-1 – PALO ALTO, CA, August 12, 2021 / Business Wire / -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppre
Where is Immune-Onc Therapeutics located?
The company Immune-Onc Therapeutics is located in Palo Alto, California, United States. It's worth noting that the company may has more corporate locations
How many employees does Immune-Onc Therapeutics approximately have?
As of the latest available information Immune-Onc Therapeutics has around 11-50 employees worldwide.
When was Immune-Onc Therapeutics founded?
Immune-Onc Therapeutics was founded in 2016
In which industries does Immune-Onc Therapeutics mainly work?
The company Immune-Onc Therapeutics has it's main focus in the industries of Science and Engineering, Biotechnology, Health Care
Teclison Limited
United States
1-10 Employees
2015
Morphogenesis
United States
11-50 Employees
1995
Exinda Therapeutics, LLC
United States
1-10 Employees
2013
ITeos Therapeutics
United States
11-50 Employees
2011
Revitope Oncology
United States
1-10 Employees
2014
CANCER CURES 4 KIDS
United States
2014
Iovance Biotherapeutics
United States
251-500 Employees
2007
Domain Therapeutics
France
11-50 Employees
2001
Topics which have been searched by others and may be interesting for you:
